<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841646</url>
  </required_header>
  <id_info>
    <org_study_id>V87P11</org_study_id>
    <secondary_id>2008-000895-25</secondary_id>
    <nct_id>NCT00841646</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects</brief_title>
  <official_title>A Phase II, Open-label, Multi-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study will evaluate the immunogenicity, safety and tolerability of two doses of&#xD;
      monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a&#xD;
      surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult and Elderly&#xD;
      Subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of antibody response to a monovalent inactivated flu vaccine adjuvanted with MF59 and uses a surface antigen from a potential pandemic homologous virus strain candidate (H5N1), as measured by HI test,MN test,SRH test,on day 0,21,42 and 201</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of safety of the monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult and Elderly Subjects.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">343</enrollment>
  <condition>Prepandemic Influenza Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent inactivated influenza vaccine</intervention_name>
    <description>2 doses of monovalent inactivated influenza vaccine with adjuvant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 18 years of age and older who are mentally competent and who have signed&#xD;
             an informed consent form after having received a detailed explanation of the study&#xD;
             protocol;&#xD;
&#xD;
          -  In good health as determined by:&#xD;
&#xD;
               1. Medical history,&#xD;
&#xD;
               2. Physical examination,&#xD;
&#xD;
               3. Clinical judgment of the Investigator;&#xD;
&#xD;
          -  Able to understand and comply with all study procedures and to complete study diaries,&#xD;
             can be contacted, and will be available for all study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous receipt of any H5 vaccine;&#xD;
&#xD;
          -  Receipt of another investigational agent within 4 weeks, or before completion of the&#xD;
             safety follow-up period in another study, whichever is longer, prior to enrollment and&#xD;
             unwilling to refuse participation in another clinical study through the end of the&#xD;
             study;&#xD;
&#xD;
          -  Experienced any acute disease or infection requiring systemic antibiotic or antiviral&#xD;
             therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable)&#xD;
             within the past 7 days;&#xD;
&#xD;
          -  Experienced fever (defined as axillary temperature 38.0°C) within 3 days prior to&#xD;
             Visit 1;&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  Females of childbearing potential who refuse to use an acceptable method of birth&#xD;
             control for the duration of the study. Adequate contraception is defined as hormonal&#xD;
             (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g.,&#xD;
             condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD),&#xD;
             or monogamous relationship with vasectomized partner who has been vasectomized for 6&#xD;
             months or more prior to the subject's study entry;&#xD;
&#xD;
          -  Any serious disease, such as:&#xD;
&#xD;
               1. Medically significant cancer,&#xD;
&#xD;
               2. Autoimmune disease (including rheumatoid arthritis and diabetes mellitus type 1),&#xD;
&#xD;
               3. Medically significant diabetes mellitus type 2,&#xD;
&#xD;
               4. Medically significant chronic pulmonary disease,&#xD;
&#xD;
               5. Medically significant acute or progressive hepatic disease,&#xD;
&#xD;
               6. Medically significant acute or progressive renal disease;&#xD;
&#xD;
               7. Medically significant acute or progressive neurological disease;&#xD;
&#xD;
          -  Surgery planned during the study period;&#xD;
&#xD;
          -  Bleeding diathesis;&#xD;
&#xD;
          -  Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,&#xD;
             neomycin or polymyxin or any other component of the study vaccine;&#xD;
&#xD;
          -  History of any neurological symptoms or signs following administration of any vaccine,&#xD;
             or anaphylactic shock following administration of any vaccine;&#xD;
&#xD;
          -  Known or suspected impairment/alteration of immune function, for example, resulting&#xD;
             from:&#xD;
&#xD;
               1. Receipt of immunosuppressive therapy (any systemic corticosteroid therapy or&#xD;
                  cancer chemotherapy), Inhaled and topical steroids are allowed&#xD;
&#xD;
               2. Receipt of immunostimulants,&#xD;
&#xD;
               3. High risk for developing an immunocompromising disease;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pestlőrinc-Pestszentimre Egészségügyi Szolgáltató KFT</name>
      <address>
        <city>Budapest</city>
        <zip>1183</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun Megyei Kórház Tüdőgondozó Intézet</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <results_reference>
    <citation>Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. Clin Vaccine Immunol. 2012 Dec;19(12):1943-8. doi: 10.1128/CVI.00373-12. Epub 2012 Oct 17.</citation>
    <PMID>23081815</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

